Dr. Young on Other Options for Managing Bleeding in Children With Cancer

Guy Young, MD
Published: Monday, Oct 23, 2017



Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses other options for managing bleeding in children with cancer.

For hospitalized children with cancer who develop a blood clot, bivalirudin (Angiomax), an intravenous-direct thrombin inhibitor, can be better than the traditionally-used heparin therapy, says Young.
 
SELECTED
LANGUAGE


Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses other options for managing bleeding in children with cancer.

For hospitalized children with cancer who develop a blood clot, bivalirudin (Angiomax), an intravenous-direct thrombin inhibitor, can be better than the traditionally-used heparin therapy, says Young.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x